Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions

Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Shilpa, Gill, David, Poole, Austin, Agarwal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332938/
https://www.ncbi.nlm.nih.gov/pubmed/28134806
http://dx.doi.org/10.3390/cancers9020015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332938/
https://www.ncbi.nlm.nih.gov/pubmed/28134806
http://dx.doi.org/10.3390/cancers9020015

Ejemplares similares